SABCS 2020 – HER2+

Prognosis and Predictors of Complete Response of Long-Term Treatment with Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients
SABCS 2020 – HER2+
In the HER2-positive metastatic breast cancer setting, trastuzumab-based therapy can support a full recovery. In patients who have achieved a long-term complete response, discontinuation of therapy may be considered appropriate. Read More ›
Phase 3 Trial of Pertuzumab Retreatment in HER2-Positive, Locally Advanced/Metastatic Breast Cancer Patients Previously Treated with Pertuzumab, Trastuzumab, and Chemotherapy
SABCS 2020 – HER2+
Retreatment with pertuzumab as either third- or fourth-line chemotherapy was both effective and reasonable in patients with HER2-positive locally advanced/metastatic breast cancer and may be considered a standard treatment practice. Read More ›

Page 2 of 2

  • 1
  • 2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Oncology Practice Management

Learn more about our family of publications.

View Our Publications

© Amplity Health. All Rights Reserved. Privacy Policy